Log in
Research by Professor Joost de Bruijn and team at QMUL from 2004 was critical to demonstrating the efficacy and commercial viability of a novel Instructive Bone Graft (IBG) product, AttraXTM. The technology, commercialised via the spin-out business Progentix Orthobiology BV (founded in 2007) was sufficiently mature by 2008 to attract series A investment of €1 million series A financing by BioGeneration Ventures. The development of AttraXTM has led to a trade sale totalling up to US$ 80 million to the global top 5 spine company NuVasive Inc. in 2009. In 2011 an exclusive distribution deal with a global top 3 dental company was signed for use of the technology in the field of dentistry and craniomaxillofacial surgery. After regulatory approval of AttraXTM in Europe (CE mark), the product was commercialised in 2011 and has been used successfully in more than eleven thousand patients (as of 2013Q3) with global reach (including EU, US, Australia, New Zealand and Brazil). Within 1 year of commercialisation, a 1.1% share of the estimated US$2 billion global spinal bone graft market has been achieved. This research has seen an economical benefit in terms of newly formed jobs from 2 FTE in 2008 to 25 FTE in 2013 at Progentix Orthobiology BV.
Biomedical devices that need to be implanted into the body typically experience the so-called foreign-body reaction: proteins adhere to the surface of the devices, leading to rapid loss of function and, eventually, to a requirement for replacing the device. Between October 2006 and September 2011, The University of Reading, in collaboration with the UK SME BioInteractions Ltd., developed and evaluated a range of new polymers for coating implantable biomedical devices, especially coronary stents and catheters. The result was a coating system that can deliver a drug controllably over a pre-defined period, leading to the commercial biomaterials platforms AdaptTM and AssistTM. This work resulted in capital investment by Biointeractions Ltd and a substantial increase in their research staffing.
A multidisciplinary team has worked in applied cell engineering implementing cell therapy and biological approaches in clinical practice since 1997. The team has two GMP accredited laboratories in hospital sites and a MHRA manufacturing license for chondrocytes and stromal /stem cells for delivery to patients in orthopaedic clinical trials. The research had impacts on health, economy, public policy and practitioners. Over 400 cartilage patients and over 150,000 knee ligament patients have benefited directly from the research, and associated turnover is over £40,000,000. Team members had influence on government, NICE and professional guidelines.
Researchers at the University of Bristol's Interface Analysis Centre played a key role in making it possible to extend the life of two nuclear power stations. Their insights into how the microstructure of reactor-core graphite degrades during service and how the material fractures enabled Magnox Ltd to construct a convincing safety case for Oldbury nuclear power station to operate for an extra four years and Wylfa power station to run for an additional four to six years. In terms of the value of the electricity generated, these extensions are worth some £5 billion. In addition, the longer lifespan of these low-carbon power sources means that less energy has to be generated from other, high-carbon sources, with the environmental benefit of an overall reduction in CO2 emissions.
Nottingham researchers constructed the world's first 3T MRI scanner, thus demonstrating the viability and benefits of high-field MRI. This provided a stimulus for magnet and MRI system manufacturers to develop 3T scanners, which have now become established as the standard platform for high-end clinical MRI studies. We estimate that since 2008: 2500 3T scanners have been installed, representing a global investment of $5 billion;and 30-40 million patient examinations have been performed with 3T MRI scanners. Technical advances which underpinned the Nottingham 3T scanner also impacted on the development of functional MRI, thus opening up a new field of medical research and clinical application. In a subsequent phase of research, the Nottingham group developed ultra-high (7T) magnetic MRI in partnership with PhiIips; forty 7T MRI scanners (current unit cost >$10M) have now been installed across the world.
Research into the biocompatibility of glass-ionomer bone cements conducted at the School of Clinical Dentistry led directly to the start-up of a UK company to manufacture a new medical device, creating jobs in the supply chain and wealth creation via international sales. The new bone cement is safe and clinically effective, and has maintained or restored hearing to improve the quality of life of over 10,000 patients worldwide since 1st January 2008. In the course of supporting this commercial partner, Sheffield's staff also contributed to other non-academic tasks.
In the UK approximately 100, 000 people have a stoma, an artificial opening in the bowel that is used to divert the flow of exudate prior to subsequent external collection. Stoma exudate is a corrosive fluid, which varies in pH and enzyme content. Therefore, it is important that the stoma seal adhesive paste operates successfully within a diverse range of physiological conditions. The novel stoma adhesive developed by Jones and colleagues through KTP funded research in the School of Pharmacy was launched by Eakin as Cohesive Paste™ and is now sold in 26 countries, with sales of more than £1M to date.
Professor Stephen Russell's fundamental and applied research on the formation, structure and properties of nonwoven fabrics has directly led to the creation and continued success of the Nonwovens Innovation and Research Institute (NIRI) Ltd a University of Leeds spin-out company. Formed in 2005 to exploit Russell's research, NIRI has grown annual sales revenue to ~£1 million supplying products and services that have enabled many medium-sized enterprises (SMEs) and global public limited companies (PLCs) to launch improved or new products, growing their market share and positively impacting consumers. Additionally, the research has enabled NIRI to independently establish and co-fund new commercial joint ventures that have resulted in the development of new IP (intellectual property)-protected products for improving global health and security. NIRI has grown its workforce to twenty (mainly University graduates) and has been profitable from the first year of trading.
Each year an estimated 1,324,000 artificial knee joints (total knee replacements — TKR) are implanted worldwide; an estimated third of these utilise an implant manufactured by DePuy International. Underlying computer-based research performed by the Bioengineering Sciences Research Group has played a central role during the development of a new design of TKR for DePuy. The design programme, the biggest in DePuy's history, had a budget in excess of US$10 million and aimed to replace the existing TKR system, which had annual sales of approximately US$100 million.
Between 2007-2010, DePuy adopted the computational techniques developed by the group as screening tools to (i) assess polyethylene wear and (ii) account for the effects of surgical variability during the early design phases. DePuy states "This research allowed us to choose the most robust solution when proceeding to mechanical testing and saved years in the design cycle. Patients also benefit from increased confidence in an implant that is able to withstand the rigors of use".
Novel biological scaffolds that regenerate with the patient's own cells have been researched, and patented and since 2008 developed, taken through successful clinical trials and commercialised. Economic impact within the REF period has been delivered through the University of Leeds spinout company Tissue Regenix plc, which has received £32M private investment, employs 35 people and is AIM listed, with a capital value of £70M. Health impact has been delivered through licensing and development by NHS Blood & Transplant Tissue Services. The biological scaffolds have demonstrated five years' successful clinical use in heart valve replacement and three years' clinical use as a commercial vascular patch.